172 related articles for article (PubMed ID: 16154799)
1. Insights into oxazaphosphorine resistance and possible approaches to its circumvention.
Zhang J; Tian Q; Chan SY; Duan W; Zhou S
Drug Resist Updat; 2005 Oct; 8(5):271-97. PubMed ID: 16154799
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and transport of oxazaphosphorines and the clinical implications.
Zhang J; Tian Q; Yung Chan S; Chuen Li S; Zhou S; Duan W; Zhu YZ
Drug Metab Rev; 2005; 37(4):611-703. PubMed ID: 16393888
[TBL] [Abstract][Full Text] [Related]
3. Glufosfamide as a new oxazaphosphorine anticancer agent.
Mazur L; Opydo-Chanek M; Stojak M
Anticancer Drugs; 2011 Jul; 22(6):488-93. PubMed ID: 21427562
[TBL] [Abstract][Full Text] [Related]
4. Reversal of resistance to oxazaphosphorines.
Zhang J; Tian Q; Zhu YZ; Xu AL; Zhou SF
Curr Cancer Drug Targets; 2006 Aug; 6(5):385-407. PubMed ID: 16918308
[TBL] [Abstract][Full Text] [Related]
5. Oxazaphosphorines: new therapeutic strategies for an old class of drugs.
Giraud B; Hebert G; Deroussent A; Veal GJ; Vassal G; Paci A
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):919-38. PubMed ID: 20446865
[TBL] [Abstract][Full Text] [Related]
6. Identification of a methylcholanthrene-induced aldehyde dehydrogenase in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance.
Sreerama L; Sladek NE
Cancer Res; 1994 Apr; 54(8):2176-85. PubMed ID: 8174125
[TBL] [Abstract][Full Text] [Related]
7. Design of new oxazaphosphorine anticancer drugs.
Liang J; Huang M; Duan W; Yu XQ; Zhou S
Curr Pharm Des; 2007; 13(9):963-78. PubMed ID: 17430192
[TBL] [Abstract][Full Text] [Related]
8. In vitro cytotoxicity testing of new generation oxazaphosphorines against human histiocytic lymphoma cells.
Opydo-Chanek M; Mazur L; Stojak M
Indian J Exp Biol; 2013 Aug; 51(8):615-22. PubMed ID: 24228385
[TBL] [Abstract][Full Text] [Related]
9. Antineoplastic drug resistance in brain tumors.
Phillips PC
Neurol Clin; 1991 May; 9(2):383-404. PubMed ID: 1682794
[TBL] [Abstract][Full Text] [Related]
10. Trofosfamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer.
Wagner A; Hempel G; Boos J
Anticancer Drugs; 1997 Jun; 8(5):419-31. PubMed ID: 9215603
[TBL] [Abstract][Full Text] [Related]
11. An overview of cyclophosphamide and ifosfamide pharmacology.
Fleming RA
Pharmacotherapy; 1997; 17(5 Pt 2):146S-154S. PubMed ID: 9322882
[TBL] [Abstract][Full Text] [Related]
12. Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines.
Sládek NE
Curr Pharm Des; 1999 Aug; 5(8):607-25. PubMed ID: 10469894
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of glufosfamide in childhood acute leukemia.
Styczynski J; Wysocki M; Kurylak A; Juraszewska E; Malinowska I; Stanczak E; Płoszynska A; Stefaniak J; Mazur B; Szczepanski T; Ras M
Anticancer Res; 2002; 22(1A):247-50. PubMed ID: 12017297
[TBL] [Abstract][Full Text] [Related]
14. Chemosensitization of solid tumors by modulation of resistance mechanisms.
Cree IA; Knight L; Di Nicolantonio F; Sharma S; Gulliford T
Curr Opin Investig Drugs; 2002 Apr; 3(4):634-40. PubMed ID: 12090736
[TBL] [Abstract][Full Text] [Related]
15. [Perfect drug targeting. Glufosfamide a new derivative].
Holzgrabe U
Pharm Unserer Zeit; 2006; 35(2):158-9. PubMed ID: 16583570
[No Abstract] [Full Text] [Related]
16. [Resistance to antineoplastic treatments: mechanisms, clinical value].
Bonnal C; Calvo F
C R Seances Soc Biol Fil; 1996; 190(4):455-66. PubMed ID: 8952896
[TBL] [Abstract][Full Text] [Related]
17. Induction of DNA breakage in U937 cells by oxazaphosphorines.
Mazur L; Opydo-Chanek M; Stojak M; Baran J; Niemeyer U
Folia Biol (Krakow); 2010; 58(1-2):15-20. PubMed ID: 20420190
[TBL] [Abstract][Full Text] [Related]
18. Clinical resistance to antimetabolites.
Spears CP
Hematol Oncol Clin North Am; 1995 Apr; 9(2):397-413. PubMed ID: 7642470
[TBL] [Abstract][Full Text] [Related]
19. Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects.
Delahousse J; Skarbek C; Desbois M; Perfettini JL; Chaput N; Paci A
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32784216
[TBL] [Abstract][Full Text] [Related]
20. Overcoming drug resistance in patients with metastatic breast cancer.
Wong ST; Goodin S
Pharmacotherapy; 2009 Aug; 29(8):954-65. PubMed ID: 19637949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
